Sugi Predict

Sugi Predict / Compounds / SCHEMBL3799795

SCHEMBL3799795

SCHEMBL3799795

COc1ccc2c(c1)NC(=O)C2=Cc1cc(C)c(C(=O)O)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 7/20 0.59
▸ PDGFRB P09619 6/20 0.59
▸ TLK2 Q86UE8 3/20 0.58
▸ FGFR1 P11362 4/20 0.55
▸ SRC P12931 1/20 0.51
▸ MDM2 Q00987 2/20 0.50
▸ FLT3 P36888 3/20 0.49
▸ KIT P10721 2/20 0.49
▸ FLT4 P35916 2/20 0.49
▸ RET P07949 1/20 0.49
▸ CCNB2 O95067 1/20 0.48
▸ CDK1 P06493 1/20 0.48
▸ CCNB1 P14635 1/20 0.48
▸ CCNB3 Q8WWL7 1/20 0.48
▸ AURKA O14965 1/20 0.48
▸ MET P08581 1/20 0.48
▸ AURKB Q96GD4 1/20 0.48
▸ AURKC Q9UQB9 1/20 0.48
▸ PDPK1 O15530 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3799794 1.00 KDR (0.59) KDRPDGFRBTLK2FGFR1SRC
SCHEMBL4464948 0.91 RET (0.60) KDRPDGFRBTLK2FGFR1SRC
SCHEMBL4464952 0.91 RET (0.60) KDRPDGFRBTLK2FGFR1SRC
SCHEMBL4457557 0.82 KDR (0.56) KDRPDGFRBTLK2FGFR1SRC
SCHEMBL4457553 0.82 KDR (0.56) KDRPDGFRBTLK2FGFR1SRC
SCHEMBL3795068 0.82 PDGFRB (0.59) KDRPDGFRBFGFR1SRCFLT3
SCHEMBL3795064 0.82 PDGFRB (0.59) KDRPDGFRBFGFR1SRCFLT3
SCHEMBL2115628 0.79 KDR (0.55) KDRPDGFRBTLK2FGFR1FLT3
SCHEMBL13755190 0.79 KDR (0.55) KDRPDGFRBTLK2FGFR1FLT3
SCHEMBL3796882 0.77 MEN1 (0.59) KDRPDGFRBFGFR1SRCRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3789027-A1 BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2021-03-10 — — EP disclosed
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2018-01-04 — — US disclosed
EP-3246046-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2017-11-22 — — EP disclosed
WO-2010120387-A1 OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2010-10-21 — — WO disclosed
US-7572924-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2009-08-11 — — US disclosed
EP-1536783-B1 SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND PFIZER ITALIA SRL (IT) 2008-08-06 — — EP disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 — — US disclosed
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2007-01-11 — — US disclosed
US-7125905-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2006-10-24 — — US disclosed
US-20050176802-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2005-08-11 — — US disclosed
EP-1427326-A4 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN INC (US) 2005-06-08 — — EP disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 — — US disclosed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 — — EP disclosed
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2004-04-01 — — US disclosed
US-20030216410-A1 Combination therapy for the treatment of cancer PHARMACIA CORPORATION 2003-11-20 — — US disclosed
US-6573293-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-03 — — US disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 — — WO disclosed
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PHARMACIA & UPJOHN COMPANY LLC 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216410-A1 Combination therapy for the treatment of cancer PTGS2, PTGES2, PTGFR KDR 498/4885PDGFRB 84/4885TLK2 907/4885
US-20050176802-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 KDR 1372/4885PDGFRB 974/4885TLK2 388/4885
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS WEE2, WEE1, ERBB2 KDR 648/4885PDGFRB 40/4885TLK2 608/4885
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, PLK2, PNCK KDR 1387/4885PDGFRB 1034/4885TLK2 380/4885
US-20040063773-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 KDR 1372/4885PDGFRB 974/4885TLK2 388/4885
US-20020156292-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, MAP3K20, PLK2 KDR 1372/4885PDGFRB 974/4885TLK2 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.